← Browse by Condition
Medical Condition
renal cell carcinoma
Total Trials
8
Recruiting Now
8
Trial Phases
Phase 1, Phase 2, Phase 2, Phase 1
ClinicalMetric tracks all active clinical trials for renal cell carcinoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Frequently Asked Questions — renal cell carcinoma Clinical Trials
How many clinical trials are currently recruiting for renal cell carcinoma?
ClinicalMetric currently tracks 8 actively recruiting clinical trials for renal cell carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 8. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for renal cell carcinoma?
renal cell carcinoma research spans Phase 1 (2 trials), Phase 2 (3 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a renal cell carcinoma clinical trial?
Eligibility criteria for renal cell carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 2
Phase 2 3
Phase 3 1
Top Sponsors
2 trials
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06424080
Recruiting
Oncological and Perioperative Outcomes of Laparoscopic Versus Robotic Partial Nephrectomy for Treatment of Renal Tumors.
Enrollment
20 pts
Location
Egypt
Sponsor
Menoufia University
NCT04623502
Recruiting
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
Enrollment
600 pts
Location
United States
Sponsor
University of Texas Southweste...
NCT07049926 Phase 1, Phase 2
Recruiting
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Enrollment
140 pts
Location
United States, Chile...
Sponsor
Merck Sharp & Dohme LLC
NCT05023265
Recruiting
Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT
Enrollment
70 pts
Location
Canada
Sponsor
Sunnybrook Health Sciences Cen...
NCT03786796 Phase 2
Recruiting
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
Enrollment
20 pts
Location
United States
Sponsor
Sidney Kimmel Comprehensive Ca...
NCT06910657 Phase 1
Recruiting
IDOV-Immune for Advanced Solid Tumors
Enrollment
78 pts
Location
United States, Austr...
Sponsor
ViroMissile, Inc.
NCT04322955 Phase 2
Recruiting
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
Enrollment
48 pts
Location
United States
Sponsor
Mark Stein
NCT07227402 Phase 3
Recruiting
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Enrollment
904 pts
Location
Argentina, Australia...
Sponsor
Merck Sharp & Dohme LLC
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology